Description: Marinomed Biotech AG, a biopharmaceutical company, develops therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders in Austria, other European countries, and internationally. It operates through two segments, Carragelose and Marinosolv. The company develops Marinosolv, a technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as eyes and nose; and. Its products pipeline includes Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Inhaleen that is in Phase I clinical trial for viral pneumonia; Budesolv, which has completed Phase III clinical trial for treatment of allergic rhinitis; Flutisolv that is Phase II clinical trials for inflammatory diseases of nose; and Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Home Page: www.marinomed.com
Hovengasse 25
Korneuburg,
2100
Austria
Phone:
43 2262 90300
Officers
| Name | Title |
|---|---|
| Mr. Andreas Grassauer | Co-Founder, Chairman of Management Board & CEO |
| Ms. Eva Prieschl-Grassauer | Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer |
| Mr. Pascal Schmidt | CFO & Member of Management Board |
| Ms. Stephanie Kniep | Head of Investor Relations |
| Dr. Angelika Bodenteich | Head of Devel. |
| Mr. Helmut Baranyovszki | Head of Staff |
| Ms. Renate Moser | Head of Bus. Devel. |
Exchange: VI
Country: AT
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 586.3194 |
| Price-to-Sales TTM: | 6.5998 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |